EDEMA2:EVALUATION OF DX-88'S EFFECTS IN MITIGATING ANGIOEDEMA, AN OPEN LABEL STD

EDEMA2：评估 DX-88 缓解血管性水肿（一种开放标签性病）的效果

• 批准号: 7380738
• 负责人: LYNDA C SCHNEIDER
• 金额: $ 3.77万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380738
• 关键词: EDEMA2; EVALUATION; DX; 88; EFFECTS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objectives: This is an open label study designed to assess the safety and effectiveness of repeated dosing of DX-88 in patients with hereditary angeoedema (HAE). Primary endpoints are: >The proportion of successful outcomes i.e., attack resolution begun by four hours after a single dose and maintained for greater than 24 hours after a single dose. > The proportion of patients who have a partial response, that is an initial response to the infusion followed by a relapse 4 - 24 hours after the infustion. > Sa

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。主要目的：这是一项开放标签研究，旨在评估反复给药DX-88治疗遗传性血管性水肿（HAE）患者的安全性和有效性。主要终点为：>成功结果的比例，即在单次给药后4小时开始发作缓解，并在单次给药后持续24小时以上。>有部分反应的患者比例，即对输注有初步反应，但在输注后4 - 24小时复发。> Sa